RNS Number : 8774G
Kromek Group PLC
24 July 2023

24 July 2023

Kromek Group plc
("Kromek" or the "Group")

Appointment of Joint Broker

Kromek (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, announces the appointment of Cenkos Securities plc as joint broker to the Group with immediate effect. finnCap Ltd will continue to act as the Group's nominated adviser and joint broker.

For further information, please contact:

Kromek Group plc	
Arnab Basu, CEO	+44 (0)1740 626 060
Paul Farquhar, CFO	
finnCap Ltd (Nominated Adviser and Joint Broker)	
Geoff Nash/Seamus Fricker/George Dollemore - Corporate Finance	+44 (0)20 7220 0500
Tim Redfern/Charlotte Sutcliffe - ECM	
Cenkos Securities plc (Joint Broker)	
Giles Balleny - Corporate Finance	+44 (0)20 7397 8900
Michael Johnson/Tamar Cranford-Smith - Sales	
Gracechurch Group (Financial PR)	
Harry Chathli/Claire Norbury/Henry Gamble	+44 (0)20 4582 3500

Kromek Group plc

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPFLFLTDIIVFIV